Vnitr Lek 2013, 59(5):397-401

A fixed dose combination of telmisartan, and a thiazide diuretic in the treatment of hypertension

J. Vítovec1,*, J. Slíva2
1 I. interní kardio-angiologická klinika Lékařské fakulty MU a FN u sv. Anny Brno, přednostka prof. MUDr. Lenka Špinarová, Ph.D., FESC
2 Ústav farmakologie 3. lékařské fakulty UK Praha, přednosta prof. MUDr. Jan Bultas, CSc.

The article gives an overview of the risk factors for hypertension and the appropriate indication for using a fixed combination of telmisartan and hydrochlorothiazide. It cites large, multi-centre clinical trials that demonstrate the efficacy and safety of telmisartan in patients with hypertension and also a meta-analysis of treatment with either telmisartan alone (TELMI) or in combination with hydrochlorothiazide (HCTZ) which shows that it is a very well tolerated and safe treatment for patients across a wide age range.

Keywords: hypertension; fixed dose combination; telmisartan; hydrochlorothiazide

Received: April 29, 2013; Published: May 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vítovec J, Slíva J. A fixed dose combination of telmisartan, and a thiazide diuretic in the treatment of hypertension. Vnitr Lek. 2013;59(5):397-401.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Wald DS, Law M, Morris JK et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009; 122: 290-300. Go to original source... Go to PubMed...
    2. Corrao G, Nicotra F, Parodi A et al. Cardiovascular protection by initial and subsequent combination of antihypertensive drugs in daily life practice. Hypertension 2011; 58: 566-572. Go to original source... Go to PubMed...
    3. Dickson M, Plauschinat CA. Racial differences in medication compliance and healthcare utilization among hypertensive Medicaid recipients: fixed-dose vs free-combination treatment. Ethn Dis 2008; 18: 204-209.
    4. Weber MA, Jamerson K, Bakris GL et al. Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. Lancet 2013; 381: 537-545. Go to original source... Go to PubMed...
    5. Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559. Go to original source... Go to PubMed...
    6. Verdecchia P, Gentile G, Angeli F et al. Beyond blood pressure: evidence for cardiovascular, cerebrovascular, and renal protective effects of renin-angiotensin system blockers. Ther Adv Cardiovasc Dis 2012; 6: 81-91. Go to original source... Go to PubMed...
    7. Tobe SW, Clase CM, Gao P et al. ONTARGET and TRANSCEND Investigators. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies. Circulation 2011; 123: 1098-1107. Go to original source... Go to PubMed...
    8. Ries UJ, Mihm G, Narr B et al. 6-Substituted benzimidazoles as new nonpeptide angiotensin II receptor antagonists: synthesis, biological activity, and structure-activity relationships. J Med Chem 1993; 36: 4040-4051. Go to original source... Go to PubMed...
    9. Kakuta H, Sudoh K, Sasamata M et al. Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers. Int J Clin Pharmacol Res 2005; 25: 41-46.
    10. Benson SC, Pershadsingh HA, Ho CI et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004; 43: 993-1002. Go to original source... Go to PubMed...
    11. Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet 2000; 355: 637-645. Go to original source... Go to PubMed...
    12. Parati G, Bilo G, Redon J. The effects of telmisartan alone or with hydrochlorothiazide on morning and 24-h ambulatory BP control: results from a practice-based study (SURGE 2). Hypertens Res 2013; 36: 322-327. Go to original source... Go to PubMed...
    13. Lacourcière Y, Gil-Extremera B, Muller O et al. Efficacy and tolerability of fixed-dose combinations of telmisartan plus HCTZ with losartan plus HCTZ in patients with essential hypertension. Int J Clin Pract 2003; 57: 273-279. Go to original source... Go to PubMed...
    14. Takagi H, Mizuno Y, Goto SN et al. Overview of telmisartan for blood pressure reduction among angiotensin II receptor blockers: A meta-analysis of head-to-head randomized trials. Int J Cardiol 2012; http://dx.doi.org/10.1016/j.ijcard.2012.11.086 Go to original source... Go to PubMed...
    15. Schumacher H, Mancia G. The safety profile of telmisartan as monotherapy or combined with hydrochlorothiazide: A retrospective analysis of 50 studies. Blood Press Suppl 2008; 1: 32-40. Go to original source... Go to PubMed...
    16. Lacourcière Y, Tytus R, O'Keefe D et al. Efficacy and tolerability of a fixed-dose combination of telmisartan plus hydrochlorothiazide in patients uncontrolled with telmisartan monotherapy. J Hum Hypertens 2001; 15: 763-770. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.